Welcome to our dedicated page for Lantheus Holding news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holding stock.
Lantheus Holdings, Inc. reports news on its radiopharmaceutical business, including diagnostic imaging agents, radiotherapeutic assets, regulatory decisions and financial results. The company organizes revenue around Radiopharmaceutical Oncology, Precision Diagnostics and Strategic Partnerships and Other Revenue, with products used by hospitals, independent imaging centers, government facilities and distribution partners in the United States and abroad.
Recurring updates include quarterly earnings, business guidance, FDA activity for products such as PYLARIFY TruVu, PYLARIFY, Lutetium Lu 177 Dotatate (PNT2003) and LNTH-2501, share repurchases, investor presentations and strategic updates involving radiodiagnostics and radiotherapeutic programs.
Lantheus Holdings (NASDAQ: LNTH) announced an offering of $500 million in convertible senior notes due 2027, with an option for an additional $75 million. These senior unsecured notes will be guaranteed by Lantheus Medical Imaging, and maturity is set for December 15, 2027. Proceeds will fund stock repurchases and general corporate purposes. The board has authorized up to $150 million for repurchases, with $75 million allocated for buying shares from note purchasers. The offering is limited to qualified institutional buyers under Rule 144A.
Lantheus Holdings (NASDAQ: LNTH) has appointed Amanda Morgan as Senior Vice President, Commercial, effective November 29, 2022. Reporting to COO Paul Blanchfield, Morgan will oversee all commercial activities, including Sales, Marketing, and Market Access. With over 20 years in healthcare, she previously served as Chief Revenue and Customer Officer at Acadia Pharmaceuticals and held senior roles at Shire Plc. Her leadership is anticipated to enhance the company's commercial strategy and patient outcomes.
Lantheus Holdings (NASDAQ: LNTH) announced the approval of the Import Drug License for DEFINITY, a diagnostic ultrasound enhancing agent, by China's National Medical Products Administration. DEFINITY is indicated for patients with suboptimal echocardiograms, helping to identify the left ventricular endocardial border. The commercialization will be handled by CR Double-Crane in China. This move aims to address the growing incidence of cardiovascular disease in China, where 20% of adults are affected.
Lantheus Holdings (NASDAQ: LNTH) has entered into a strategic collaboration with POINT Biopharma Global (NASDAQ: PNT) for exclusive worldwide rights to two late-stage radiopharmaceuticals, PNT2002 and PNT2003. Lantheus will pay $260 million upfront, with potential milestone payments reaching approximately $1.8 billion. The collaboration aims to enhance Lantheus’ prostate cancer portfolio and drive long-term revenue growth. Both companies will fund and complete clinical trials, with Lantheus retaining commercialization rights post-FDA approval.
Lantheus Holdings (NASDAQ: LNTH) announced that CFO Bob Marshall will present at the Jefferies London Healthcare Conference on November 16, 2022, at 8:00 a.m. GMT (3 a.m. EST). The live webcast can be accessed on the company's website, with a replay available for 30 days post-presentation. Lantheus has over 65 years of experience in improving patient outcomes through diagnostics, radiotherapeutics, and AI solutions, aimed at helping clinicians Find, Fight, and Follow disease. The company is based in Massachusetts, with additional offices in New Jersey, Canada, and Sweden.
Lantheus reported a remarkable third quarter for 2022, achieving worldwide revenue of $239.3 million, marking a 134.4% increase year-over-year. The company's GAAP net income surged to $61.2 million or $0.86 per fully diluted share, compared to a loss of $13.4 million in the same quarter of 2021. Adjusted fully diluted EPS was $0.99, up from $0.08 a year earlier. With operating cash flow at $93.6 million and free cash flow of $87.5 million, Lantheus also provided positive guidance for Q4 and updated full-year 2022 expectations.
Lantheus Holdings (NASDAQ: LNTH) announced a conference call and webcast for November 3, 2022, at 8:00 a.m. ET to discuss Q3 2022 financial and operating results. The company encourages participants to register online ahead of time to avoid delays. A replay will be available approximately two hours post-event for 30 days. Lantheus, with over 60 years of experience, focuses on improving patient outcomes through diagnostics and AI solutions in healthcare.
Lantheus Holdings (NASDAQ: LNTH) presented AI data at the 2022 EANM Annual Meeting in Barcelona, showcasing the clinical utility of PYLARIFY AI for prostate cancer treatment. Key highlights include a top-rated presentation demonstrating a strong association between automated PSMA scores and PSA response in prostate cancer, indicating that a quantitative PSMA score can effectively assess treatment response. The company also unveiled new adaptive methodologies improving tumor burden quantification in PSMA PET/CT imaging. PYLARIFY AI is FDA-cleared and aims to enhance diagnostic efficiency.
The Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical has met its co-primary endpoints for detecting Coronary Artery Disease (CAD), exceeding 60% in both sensitivity and specificity. The trial demonstrated higher efficacy than SPECT Myocardial Perfusion Imaging, with over 600 patients participating across multiple regions. If approved, [18F]flurpiridaz’s longer half-life could significantly increase patient access to PET MPI, enhancing diagnostic accuracy and patient outcomes, as noted by experts at the ASNC Congress.
GE Healthcare and Lantheus Holdings have announced that their Phase III clinical trial of the investigational radiotracer [18F]flurpiridaz has successfully met co-primary endpoints for detecting Coronary Artery Disease (CAD), exceeding 60% in both sensitivity and specificity. This trial demonstrated superior diagnostic efficacy compared to SPECT Myocardial Perfusion Imaging. With a half-life approximately 12 times longer than existing PET tracers, [18F]flurpiridaz could significantly improve patient access to PET MPI if approved.